AGP Executive Report
Last update: 11 hours agoRare Disease Access: Georgia has signed an agreement to buy givinostat (Duvyzat®) for Duchenne muscular dystrophy, aiming to include it in the national disease-management program for eligible patients aged 6+ who can still move. EU Cancer Approval: The European Commission approved datopotamab deruxtecan-dlnk (Dato-DXd/Datroway) as first-line monotherapy for certain metastatic triple-negative breast cancer patients who can’t receive PD-1/PD-L1 inhibitors, based on the TROPION-Breast02 trial. Public Health & Travel Hygiene: Doctors warn that the “chewing gum walls” trend—now spotted in Verona—can spread bacteria and create “walls of bacteria” on historic sites. Heat & Health Risk (Italy): Italy’s heatwave coverage continues, with multiple cities under red alert as extreme temperatures raise infectious-disease and health risks. Healthcare Industry in Italy: Celltrion expands biosimilar orders and direct sales in Italy, signaling continued momentum for biologics supply and access.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
